Oleg E. Akilov
Experienced in Peripheral T-Cell Lymphoma

Dr. Oleg E. Akilov

Dermatology
University Of Pittsburgh Physicians
5230 Centre Ave, Suite 509, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Peripheral T-Cell Lymphoma
University Of Pittsburgh Physicians
5230 Centre Ave, Suite 509, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Oleg Akilov is a Dermatologist in Pittsburgh, Pennsylvania. Dr. Akilov is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, and Sezary Syndrome.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Specialties
Dermatology
Licenses
Dermatology in PA
Hospital Affiliations
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
5230 Centre Ave, Suite 509, Pittsburgh, PA 15232
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
580 S Aiken Ave, Pittsburbh, PA 15232
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients with Sézary Syndrome At Single-cell Resolution
Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients with Sézary Syndrome At Single-cell Resolution
Enrollment Status: Recruiting
Publish Date: January 08, 2025
Intervention Type: Drug, Device
Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Enrollment Status: Recruiting
Publish Date: January 08, 2025
Intervention Type: Other
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Duvelisib, Nivolumab
Study Phase: Phase 1
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)
Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Micro needle array-Doxorubicin
Study Phase: Phase 1
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

83 Total Publications

Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.
Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.
Journal: Dermatopathology (Basel, Switzerland)
Published: May 15, 2025
Similar Doctors
Experienced in Peripheral T-Cell Lymphoma
Dr. David M. Lemchak
Family Medicine | Dermatology
Experienced in Peripheral T-Cell Lymphoma
Dr. David M. Lemchak
Family Medicine | Dermatology

Dermeve PC

607 Washington Rd, Lower Level, 
Pittsburgh, PA 
 (7.4 miles away)
412-563-0217
Experience:
9+ years
Languages Spoken:
English
See accepted insurances

David Lemchak is a Dermatologist in Pittsburgh, Pennsylvania. Dr. Lemchak has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Neurocutaneous Melanosis, Liver Spots, Universal Acquired Melanosis, and Familial Atypical Multiple Mole Melanoma Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Akilov's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile